The Medicines Company
Most Recent
Where Stanley Druckenmiller Is Bullish
Last week, Duquesne Family Office, managed by Stanley Druckenmiller, filed its Q3 13F with the SEC. We’ll look at the fund’s top holdings, buys, and sells.
What Alnylam Pharmaceuticals’ Bottom Line Trend Indicates
Alnylam Pharmaceuticals’ interest income increased from $2.58 million in the second quarter of 2017 to $6.1 million in the second quarter of 2018.
A Look at Mylan’s Launch of Its Generic Angiomax Injection
On June 1, Mylan (MYL) announced the launch of a generic version of the Medicines Company’s (MDCO) Angiomax, which is bivalirudin.
Behind Valeant’s Branded Drugs: Other 3Q17 Performances
In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.
Vabomere: Major Addition to The Medicines Company’s Portfolio?
On August 29, 2017, the FDA approved The Medicines Company’s (MDCO) Vabomere for treating adulating patients suffering with complicated urinary tract infections.
Inclisiran: Long-Term Growth Driver for The Medicines Company?
According to a Monte Carlo simulation performed at Harvard, it’s estimated that 5.0 million patients in the United States stand to benefit from PCSK9 inhibitor therapy.
The Medicines Company May Report Steep Revenue Decline in 2017
In 2Q17, The Medicines Company (MDCO) reported a net loss from continuing operations of $397.3 million, which was a significant fall from $181.8 million in 2Q16.
Analysts’ Recommendations for The Medicines Company in October
In 2Q17, The Medicines Company (MDCO) reported revenues of $18.7 million, which is a fall of 66.0% on a YoY (year-over-year) basis.
IBB Mid-Caps: Medicines Company’s Carbavance, Fast-Track Status
In a press release, the Medicines Company (MDCO) announced that the FDA has granted fast-track status to Carbavance for the treatment of complicated urinary tract infections.
Small-Caps Are Topping the IBB Portfolio
Biotech stocks and ETFs had a good day on December 21 and rose marginally. The iShares Nasdaq Biotechnology ETF (IBB) rose 0.2% for the day and closed at $332.13.
The PowerShares Dynamic Pharmaceuticals ETF: PJP’s 2015 Performance
As of November 2015, PJP has outperformed the market, with a YTD return of 6.5%. The fund’s top ten holdings represent 52.41% of its total portfolio.
Performance of XBI and IBB with Respective Benchmark Indexes
The SPDR S&P Biotech ETF (XBI) fell 4.53%. It tracks the S&P Biotechnology Select Industry Index as its benchmark index, which fell 4.32% for the week ended September 4.
